Nektar Therapeutics to Showcase Innovations at Key Conferences
Nektar Therapeutics (Nasdaq: NKTR) has recently made an exciting announcement regarding its participation in some significant upcoming investor conferences. This is a notable opportunity for the company to share insights into its leading-edge developments and innovative therapies aimed at addressing serious medical conditions.
Details on Upcoming Conferences
The first major event on the schedule is the UBS Global Healthcare Conference. This conference is set to take place in the vibrant setting of Rancho Palos Verdes. Nektar is scheduled to present on November 13, and they will be sharing their latest research findings and advancements in therapies aimed at immune and chronic inflammatory diseases. For audience members who cannot attend in person, the company will provide a webcast for convenient access to the presentation. This accessibility allows a broader audience to engage with the company’s narrative.
Additional Conference Participation
Following the UBS conference, Nektar will participate in the Piper Sandler 36th Annual Healthcare Conference in New York. This event is another key platform for Nektar to showcase its innovative pipeline, including discussions on its blockbuster candidate, rezpegaldesleukin. Nektar's focus on immune response is crucial in a time when understanding treatments for autoimmune conditions is highly sought after.
Webcast Accessibility for Presentations
For those interested in Nektar's presentations, the company will stream the events via webcast. These presentations will be available not only during the live events but also for replay for a period of 30 days after the conferences. This initiative highlights the company's commitment to transparency and information dissemination, ensuring that interested stakeholders have ample opportunity to engage with their research.
One-on-One Meeting Opportunities
Nektar envisions fostering relationships and discussions during these conferences. Investors are encouraged to request one-on-one meetings with Nektar's management teams. This personal touch allows for more tailored discussions regarding company strategies, innovations, and investor interests, enhancing stakeholder engagement.
About Nektar Therapeutics
Nektar Therapeutics is a pioneering clinical-stage biotechnology company that is committed to developing transformative treatments for autoimmune and chronic inflammatory diseases. The company's promising lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), represents first-in-class technology focusing on the stimulation of regulatory T cells. Nektar is advancing this candidate through two Phase 2b clinical trials targeting conditions such as atopic dermatitis and alopecia areata.
Innovative Pipeline and Collaborations
In addition to rezpegaldesleukin, Nektar Therapeutics is exploring a robust pipeline that includes NKTR-0165, a preclinical candidate aimed at tumor necrosis factor receptor type II. Moreover, the company, alongside several partners, is testing NKTR-255, an investigational IL-15 receptor agonist, aimed at harnessing the body's immune capacity against cancer. These promising developments underline Nektar's dedication to pioneering new avenues in patient care and treatment efficacy.
Contact Information
For interested parties seeking further information, Nektar Therapeutics provides dedicated contacts for investors and media inquiries. Vivian Wu leads the communication for investor relations and can be reached at 628-895-0661. For media inquiries, Madelin Hawtin from LifeSci Communications is available at 603-714-2638.
Frequently Asked Questions
What is Nektar Therapeutics known for?
Nektar Therapeutics is recognized for its groundbreaking work in developing treatments for autoimmune and chronic inflammatory diseases.
When is the UBS Global Healthcare Conference?
Nektar is presenting at the UBS Global Healthcare Conference on November 13.
How can I access Nektar's conference presentations?
The presentations will be webcasted live and will also be available for replay for 30 days afterwards.
What is NKTR-358?
NKTR-358 is Nektar's lead product candidate, which stimulates regulatory T cells to treat autoimmune diseases.
Who can be contacted for investor inquiries?
Investors can reach out to Vivian Wu at Nektar Therapeutics by calling 628-895-0661 for inquiries.